Results 1 to 10 of about 78,599 (134)
TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Pharmaceuticals, 2021 Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
exaly +3 more sources
TRK-T3 condensate organization drives growth signaling [PDF]
Life Science AllianceThe TRK-T3 oncogenic fusion protein forms biomolecular condensates driven by a hydrophobic segment that drives both morphology and MAPK activation.
Sindy R Chavez +6 more
doaj +2 more sources
A Case of Primary Intramedullary Infantile Fibrosarcoma With an RBPMS::NTRK3 Fusion and Response to Larotrectinib. [PDF]
Neuropathol Appl NeurobiolWe report a case of primary intramedullary infantile fibrosarcoma (IFS) in a 4‐week‐old infant with rapidly progressive cervical myelopathy. Histology showed a spindle cell tumour with diffuse S100 and pan‐TRK expression. RNA sequencing identified an RBPMS::NTRK3 fusion.
Le Quang M +8 more
europepmc +2 more sources
Structural insights into the specificity of adaptor proteins Dok5 and Dok6 Docking to Trk receptors [PDF]
Cell Communication and SignalingSpecific neurotrophic signaling by Trk receptors relies on the selective recruitment of downstream adaptors such as Dok5 and Dok6, yet the structural basis underlying this selectivity has remained unresolved.
Yingyao Wu +7 more
doaj +2 more sources
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation. [PDF]
ChembiochemA homodimeric anti‐TrkB macrocyclic peptide, DiTrbL3, originally discovered by the RaPID system as monomeric form, dimerizes the TrkB receptor and activate the downstream signaling. DiTrbL3 acts as a mimic of BDNF (the natural protein ligand) and stimulates hippocampal neurons to extend axons.
Maini R +4 more
europepmc +2 more sources
TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations [PDF]
Pathology and Oncology ResearchRhabdomyosarcoma is the third most common extracranial solid tumor in childhood. Treatment of patients is multimodal, based on systemic chemotherapy and local therapy by surgery and/or radiotherapy.
Renáta Lajti +8 more
doaj +2 more sources
Comprehensive Immunophenotypic Profiling and Prognostic Value in Salivary Gland Mucoepidermoid Carcinoma [PDF]
International Dental JournalObjectives: To characterize the proliferative and immunophenotypic profiles of salivary gland mucoepidermoid carcinoma (MEC) and to explore their associations with clinicopathologic features, tumour microenvironment (TME) characteristics, Pan-TRK ...
Vy Ngoc Thuy Tran +4 more
doaj +2 more sources
F1000Research, 2023 Background: NTRK1, NTRK2, and NTRK3 are members of the neurotrophic receptor tyrosine kinases (NTRK) family, which encode TrkA, TrkB, and TrkC receptors, respectively.
Fazil Ahmad +3 more
doaj +1 more source
Molecules, 2022 The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients ...
Jie Wang +11 more
doaj +1 more source
Cells, 2020 Extraocular muscles (EOMs) show resistance to muscle dystrophies and sarcopenia. It has been recently demonstrated that they are endowed with different types of myogenic cells, all of which present an outstanding regenerative potential. Neurotrophins are
Génova Carrero-Rojas +3 more
doaj +1 more source